La vendita allo scoperto per Sage Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Sage Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Sage Therapeutics (NASDAQ:SAGE) Azioni, Report sulle vendite allo scoperto

Sage Therapeutics

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Sage Therapeutics Inc

SAGEN MI CDA INC PFD A by SAGEN MI CDA INC.

Sage Gold Inc

Sage Group (The) PLC

SAGE GROUP UNSP/ADR by Sage Group plc (The)

Sage Potash Corp

TD Cowen analyst Ritu Baral maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and lowers the price target from $10 to $9.

News

Price Target

Analyst Ratings

SAGE

TD Cowen Maintains Hold on Sage Therapeutics, Lowers Price Target to $9

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c6ab8bb85e9300015f1ad9/brian-abrahams">RBC Capital analyst Brian Abrahams </a>upgraded Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Underperform to Sector Perform and maintained the price target of $4. Sage Therapeutics shares closed at $4.91 on Wednesday. See how other analysts view this stock.</li>
<li>Morgan Stanley analyst James Faucette upgraded the rating for EVERTEC, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTC#NYSE">EVTC</a>) from Underweight to Equal-Weight and raised the price target from $33 to $35. Evertec shares closed at $34.84 on Wednesday. <a href="https://www.benzinga.com/quote/EVTC/analyst-ratings">See how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b1f43eaaa0001698f45/spiro-dounis">Citigroup analyst Spiro Dounis</a> upgraded DT Midstream, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTM#NYSE">DTM</a>) from Neutral to Buy and raised the price target from $90 to $115. DT Midstream shares closed at $102.73 on Wednesday. <a href="https://www.benzinga.com/quote/DTM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Rosenblatt analyst Catharine Trebnick upgraded Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) from Neutral to Buy and boosted the price target from $390 to $425. Palo Alto shares closed at $392.89 on Wednesday. <a href="https://www.benzinga.com/quote/PANW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Compass Point analyst Floris Van Dijkum upgraded Pebblebrook Hotel Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) from Neutral to Buy and maintained the price target of $17. Pebblebrook Hotel shares closed at $12.37 on Wednesday. <a href="https://www.benzinga.com/quote/PPEB/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PANW stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="367" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21111949/image-222-1024x367.png" alt="" class="wp-image-659212" style="width:539px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21111949/image-222-1024x367.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21111949/image-222-300x107.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21111949/image-222-768x275.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21111949/image-222-1536x550.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21111949/image-222.png 1595w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/24/11/42114009/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 5% Dividend Yields</a></li>
</ul>

Markets

Trading Ideas

EVTC

PANW

This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

RBC Capital analyst Brian Abrahams upgrades Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Underperform to Sector Perform and maintains the price target from $4 to $4.

Upgrades

RBC Capital Upgrades Sage Therapeutics to Sector Perform, Maintains Price Target to $4

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and maintains $14 price target.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $14 Price Target

On Wednesday, Sage Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>)&nbsp;revealed topline results from the Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) in participants with cognitive impairment (CI) associated with <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42084056/sage-therapeutics-announces-topline-results-from-the-phase-2-dimension-study-of-dalzanemdor-sage-7" rel="noreferrer noopener">Huntington&#8217;s Disease (HD)</a>, an inherited brain disorder that causes nerve cells in the brain to break down and die.
In the study, dalzanemdor did not demonstrate a statistically significant difference versus placebo on the primary endpoint, the change from baseline on the Symbol Digit Modalities Test (SDMT) at Day 84.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41382549/after-series-of-trial-setbacks-sage-therapeutics-to-lay-off-one-third-workforce" rel="noreferrer noopener">After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce</a>
SDMT is used for cognitive evaluation, and measures sustained attention, processing speed, visual scanning, and motor speed.&nbsp;
Analyses of secondary endpoints did not demonstrate statistically significant or clinically meaningful differences in participants treated with dalzanemdor compared to placebo.
Based on these results, the company does not plan to develop dalzanemdor further.
&#8220;We are disappointed by the results of the DIMENSION Study,&#8221; said Barry Greene, Chief Executive Officer of Sage Therapeutics.
Dalzanemdor was generally well-tolerated, and no new safety signals were observed. The majority of treatment-emergent adverse events were mild to moderate in severity.
Given these findings, the company will also close the ongoing PURVIEW Study, an open-label safety study of dalzanemdor in participants with HD.
In October, Sage Therapeutics released topline results from the Phase 2 LIGHTWAVE study to evaluate the effects of dalzanemdor (SAGE-718) in participants with mild cognitive impairment (MCI) or mild dementia due to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41228587/after-disappointing-parkinsons-data-sage-therapeutics-dalzanemdor-flunks-mid-stage-alzheimers-stu" rel="noreferrer noopener">Alzheimer's Disease (AD)</a>.
The LIGHTWAVE Study did not demonstrate a statistically significant difference from baseline in participants treated with dalzanemdor versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test score at Day 84, the study's primary outcome measure.
Price Action: SAGE stock is up 1.63% at $4.99 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/24/11/42089876/nokia-wins-multi-billion-dollar-deal-to-power-airtels-4g-and-5g-expansion-in-india" target="_blank" rel="noreferrer noopener">Nokia Wins Multi-Billion Dollar Deal To Power Airtel&#8217;s 4G And 5G Expansion In India</a></li>
</ul>

Biotech

Equities

Health Care

Movers

General

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $12.2, a high estimate of $26.00, and a low estimate of $4.00. Highlighting a 33.7% decrease, the current average has fallen from the previous average price target of $18.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1732111224_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Sage Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Perform</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$6.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$4.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sage Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sage Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Sage Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Sage Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SAGE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sage Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Sage Therapeutics</h2>
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
<h3>Sage Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Sage Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 337.08%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Sage Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -788.06% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sage Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -15.86%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Sage Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -14.18%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold.

Needham Reiterates Hold on Sage Therapeutics

Sage Therapeutics Announced Topline Results From The Phase 2 DIMENSION Study Of dalzanemdor (SAGE-718) In Participants With Cognitive Impairment (CI) Associated With Huntington's Disease (HD)

On October&nbsp;31, 2024 (the "Separation Date"), Kimi Iguchi and Sage Therapeutics, Inc. (the "Company") entered into a separation agreement (the "Iguchi Separation Agreement") providing for the resignation of Ms.&nbsp;Iguchi from her positions as the Chief Financial Officer and Treasurer of the Company and from any and all other positions she holds as an officer or employee of the Company or an officer, employee or director of any of its subsidiaries. As previously announced, Ms.&nbsp;Iguchi's departure from the Company was part of the October 2024 reorganization of the Company's business operations and reduction in the Company's workforce (the "Reorganization"). The Iguchi Separation Agreement also includes a release of claims by Ms.&nbsp;Iguchi and non-solicitation, non-disclosure and non-disparagement obligations following the Separation Date.

Management

Sage Therapeutics Announces Resignation Of Kimi Iguchi From Her Position As CFO And Treasurer Of The Co And From Any And All Other Positions She Holds As An Officer Or Employee Of The Company Or An Officer, Employee Or Director Of Any Of Its Subsidiaries

Scotiabank analyst George Farmer maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Sector Outperform and lowers the price target from $17 to $14.

Scotiabank Maintains Sector Outperform on Sage Therapeutics, Lowers Price Target to $14

Piper Sandler analyst Yasmeen Rahimi reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Overweight and lowers the price target from $52 to $26.

Piper Sandler Reiterates Overweight on Sage Therapeutics, Lowers Price Target to $26

<h3>Gainers</h3>
<ul>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock moved upwards by 106.1% to $4.18 during Wednesday's regular session. The market value of their outstanding shares is at $4.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock moved upwards by 51.76% to $0.63. The company's market cap stands at $9.3 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock rose 35.29% to $1.34. The company's market cap stands at $58.8 million. </li>
<li>Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) stock rose 33.25% to $53.46. The company's market cap stands at $2.4 billion. The company's, Q3 earnings came out today. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock increased by 32.83% to $14.27. The company's market cap stands at $309.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) shares rose 31.66% to $5.17. The company's market cap stands at $55.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock decreased by 37.0% to $0.2 during Wednesday's regular session. The company's market cap stands at $2.0 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) stock declined by 25.56% to $22.93. The company's market cap stands at $692.4 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares declined by 20.46% to $6.75. The market value of their outstanding shares is at $411.7 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) shares decreased by 20.14% to $24.36. The company's market cap stands at $4.1 billion. The company's, Q3 earnings came out today. </li>
<li>Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares declined by 15.32% to $10.98. The market value of their outstanding shares is at $613.5 million. As per the news, the Q3 earnings report came out today. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares decreased by 15.06% to $18.89. The company's market cap stands at $4.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANAB

APDN

CALC

CRMD

CVRX

ENSC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

OMCL

OPCH

THAR

12 Health Care Stocks Moving In Wednesday's Intraday Session

Oppenheimer analyst Jay Olson maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Perform and lowers the price target from $9 to $8.

Oppenheimer Maintains Perform on Sage Therapeutics, Lowers Price Target to $8

Truist Securities analyst Joon Lee maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and lowers the price target from $13 to $8.

Truist Securities Maintains Hold on Sage Therapeutics, Lowers Price Target to $8

WIIM

Sage Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results. Additionally, HC Wainwright & Co. cut its price target on the stock from $25 to $14.

HC Wainwright &amp; Co. analyst Douglas Tsao maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and lowers the price target from $25 to $14.

HC Wainwright & Co. Maintains Neutral on Sage Therapeutics, Lowers Price Target to $14

Guidance

Sage Therapeutics Does Not Anticipate Receipt Of Any Milestone Payments From Collaborations In Remainder Of 2024; Anticipates ZULRESSO Use Will Continue To Decrease And Has Decided To No Longer Make ZULRESSO Commercially Available As Of December 31, 2024

Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) reported quarterly losses of $(1.53) per share which missed the analyst consensus estimate of $(1.52) by 0.66 percent. The company reported quarterly sales of $11.871 million which beat the analyst consensus estimate of $10.802 million by 9.89 percent. This is a 337.08 percent increase over sales of $2.716 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Sage Therapeutics Q3 2024 GAAP EPS $(1.53) Misses $(1.52) Estimate, Sales $11.871M Beat $10.802M Estimate

Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) is preparing to release its quarterly earnings on Tuesday, 2024-10-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Sage Therapeutics to report an earnings per share (EPS) of $-1.55.
Sage Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.04, leading to a 10.87% drop in the share price on the subsequent day.

<img src="https://www.benzinga.com/files/images/story/2024/1730131343_0.png" alt="eps graph" />
<h3>Performance of Sage Therapeutics Shares</h3>
Shares of Sage Therapeutics were trading at $8.01 as of October 25. Over the last 52-week period, shares are down 57.32%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/SAGE/earnings">To track all earnings releases for Sage Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sage Therapeutics's Earnings: A Preview

RBC Capital upgraded Sage Therapeutics (SAGE) to Sector Perform from Underperform with an unchanged price target of $4. The firm says that this mor...

RBC upgrades Sage to Sector Perform with negative thesis played out

RBC Capital upgraded Sage Therapeutics (SAGE) to Sector Perform from Underperform with an unchanged price target of $4. Published first on TheFly –...

Sage Therapeutics upgraded to Sector Perform from Underperform at RBC Capital

TD Cowen analyst Ritu Baral maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $9.00. Ritu Bara...

SAGE Therapeutics: Hold Rating Amid Dalzanemdor's Phase 2 Failure and Valuation Adjustments

Analyst Tazeen Ahmad from Bank of America Securities reiterated a Sell rating on SAGE Therapeutics (SAGE – Research Report) and decreased the price...

SAGE Therapeutics: Analyst Reiterates Sell Rating Amid Pipeline Setbacks and Prescriber Challenges

BofA lowered the firm's price target on Sage Therapeutics (SAGE) to $4 from $7 and keeps an Underperform rating on the shares after the company rep...

Sage Therapeutics price target lowered to $4 from $7 at BofA

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The company's sh...

Truist Financial Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)

In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The company's shares...

Oppenheimer Sticks to Its Hold Rating for SAGE Therapeutics (SAGE)

Scotiabank analyst George Farmer maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $14.00. The ...

Scotiabank Sticks to Its Buy Rating for SAGE Therapeutics (SAGE)

TD Cowen lowered the firm's price target on Sage Therapeutics (SAGE) to $9 from $10 and keeps a Hold rating on the shares. The firm noted they anno...

Sage Therapeutics price target lowered to $9 from $10 at TD Cowen

Sage raised to sector perform by RBC in wake of drug failure

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAGE

Legal

SAGE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important October 28 Deadline in Securities Class Action – SAGE

SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit

Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending Class Action - SAGE

Small Cap

SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE

DEADLINE ALERT for OM, SAGE, and SMCI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease

Comments

Sage Therapeutics

Vendite allo scoperto

Sage Therapeutics (NASDAQ:SAGE) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO